- Published on
Emergency and Acute Medicine – Hypertrophic Cardiomyopathy
Core Overview
Hypertrophic cardiomyopathy (HCM) is a genetic disorder of the cardiac sarcomere caused by numerous mutations, resulting in a hypertrophied, nondilated left ventricle (and rarely right ventricle) without another cause such as hypertension or aortic stenosis. Phenotypic expression is highly variable. Two major forms exist: nonobstructive HCM, accounting for approximately 75% of patients with an estimated annual mortality of ~1%, and obstructive hypertrophic cardiomyopathy (HOCM), accounting for ~25% with more severe disease and an estimated annual mortality of ~2%.
HCM can present at any age, from neonates to the elderly, but most cases manifest during childhood or adolescence, often coinciding with the pubertal growth spurt. Disease diagnosed at younger ages is typically more severe. A small subset progresses to reduced left ventricular systolic function later in life. Adult-onset presentations are not uncommon and are frequently misdiagnosed as asthma, COPD, deconditioning, or sleep apnea. Lethal ventricular arrhythmias are more common in younger patients, while supraventricular arrhythmias increase with age. Atrial fibrillation is common and often poorly tolerated. HCM is the most common cause of atraumatic sudden death in young athletes under 35 years of age. Prevalence is approximately 1 in 500 adults based on echocardiographic screening.
Structural and Pathophysiologic Features
Pathology is characterized by marked and irregular ventricular wall thickening with myofibrillar disarray and fibrin deposition, predominantly affecting the high-pressure left ventricle. Septal hypertrophy is usually more pronounced than free wall thickening. In obstructive disease, hypertrophy may regress if outflow obstruction is relieved. Some phenotypes demonstrate progressive wall thinning with age, typically following marked hypertrophy earlier in life. Diastolic stiffness leads to atrial dilation. Microvascular dysfunction occurs due to impaired vasodilation, intimal thickening, and perivascular collagen deposition.
Long-Term Outpatient Management Principles
Management focuses on avoiding volume depletion and excessive cardiac demand, with therapy tailored to hypertrophy severity and distribution. Pharmacologic treatment includes beta-blockers or verapamil to slow heart rate and prolong diastole. Implantable cardioverter-defibrillators are indicated in patients with prior syncope, cardiac arrest, family history of sudden death, nonsustained ventricular tachycardia, abnormal blood pressure response to exercise, or massive hypertrophy. Septal reduction strategies include alcohol septal ablation and surgical septal myectomy, with improving outcomes at experienced centers.
Genetic Risk Profile
HCM was the first cardiac disease with an identified genetic basis (1989). It follows an autosomal-dominant inheritance pattern with more than 10 associated genes, most encoding sarcomeric proteins. Over 700 distinct mutations have been identified, with high penetrance and marked phenotypic variability. Some genotypes carry significantly higher risk of sudden death. Routine genotype-based risk stratification remains impractical due to complexity and incomplete understanding of modifier genes and environmental factors. Certain mutations involving cell membrane pumps are associated with increased arrhythmogenic risk.
Clinical Presentation
Symptoms often correlate with exertion or sudden upright posture, both of which reduce venous return and ventricular filling. Severity depends on hypertrophy location and extent. Common symptoms include exertional dyspnea, shortness of breath, postprandial or exertional angina, presyncope, syncope, congestive heart failure, cardiovascular collapse, and dysrhythmias. Paroxysmal atrial fibrillation may precipitate rapid deterioration, particularly in heart failure, and increases thromboembolic risk. Ventricular tachycardia or fibrillation may cause sudden death, while bradyarrhythmias are rare.
Patients may have a history of septal myectomy or alcohol ablation, with associated risks of conduction abnormalities or septal rupture. High-risk individuals may have implanted defibrillators. A family history of unexplained sudden death or known HCM is a critical diagnostic clue.
Pediatric Considerations
Disease severity may increase during adolescence. Any child with unexplained syncope, especially during exertion, warrants detailed family history (standard three-generation pedigree) and specialist referral.
Physical Examination Findings
Findings may be absent or subtle in nonobstructive disease. In obstructive HCM, findings may include a loud left-sided S4, a double apical impulse, and a crescendo–decrescendo midsystolic murmur best heard at the left sternal border. The murmur increases with standing or Valsalva and decreases with squatting, recumbency, or handgrip. Mitral regurgitation is common; radiation to the axilla suggests associated mitral insufficiency.
Electrocardiographic Features
ECG is abnormal in over 90% of patients. Findings include T-wave inversion >1 mm in multiple leads, ST-segment depression >0.5 mm, deep Q waves (>3 mm or >40 ms) excluding leads III and aVR, prolonged P waves with negative terminal forces in V1, and nonspecific intraventricular conduction delay >140 ms. Athletic ECG variants require careful interpretation, especially in non–African-Caribbean athletes over 16 years.
Laboratory and Imaging Evaluation
Routine laboratory testing has no diagnostic value in the emergency setting. Genetic testing is outpatient-focused. Chest radiography is usually normal but may show left ventricular free wall bulging, atrial enlargement, or pulmonary vascular redistribution. Transthoracic echocardiography with Doppler is the diagnostic cornerstone, demonstrating LV wall thickness >15 mm in adults (or ≥13–14 mm with supportive features), small or normal LV cavity, systolic outflow obstruction, and diastolic dysfunction. In children, wall thickness ≥2 standard deviations above the mean is diagnostic. Cardiac MRI supplements echocardiography, offering detailed assessment of hypertrophy distribution and fibrosis. Stress thallium and PET imaging may identify ischemia.
Differential Diagnosis
Consider vasovagal syncope, heat illness, aortic or pulmonic stenosis, ventricular septal defect, mitral regurgitation or prolapse, and coronary artery disease. Angina or heart failure in HCM carries higher risk than in non-HCM populations.
Emergency Management Principles
Suspect HCM in patients who deteriorate with standard heart failure, ischemia, or supraventricular tachycardia treatment, and in young athletes collapsing during exertion. Patients are highly sensitive to preload reduction and impaired diastolic filling. Initial management includes airway stabilization, oxygen, IV access, cardiac monitoring, and pulse oximetry. Patients may need to remain supine.
Avoid routine vasodilators for CHF or angina, as they may precipitate collapse. If hypotension occurs, administer cautious fluid boluses. Even mild hypovolemia can significantly reduce cardiac output. Rate control and improved diastolic filling are central goals. Beta-blockers are first-line therapy; verapamil is useful but nifedipine is relatively contraindicated due to vasodilation.
Supraventricular dysrhythmias are treated initially with beta-blockers or calcium channel blockers. Amiodarone is the drug of choice for ventricular dysrhythmias or refractory cases. Early electrical cardioversion is recommended for new-onset atrial fibrillation with heart failure.
Key Medications
Amiodarone, propranolol, verapamil, phenylephrine (for refractory hypotension without inotropic effect), and diltiazem (contraindicated in children under 12) may be used with careful hemodynamic assessment. All medications must be evaluated for their impact on outflow tract obstruction.
Disposition Decisions
Admission is required for unexplained syncope, heart failure, angina, or hemodynamically significant tachydysrhythmias, often to ICU level care. Discharge may be considered only when hypertrophy is an incidental finding without personal or family history of syncope or sudden death, with urgent cardiology follow-up arranged. Patients must be counseled to avoid exertion or situations that reduce preload until evaluated.
Clinical Pitfalls and Key Insights
Genetic and phenotypic diversity complicates diagnosis and risk stratification. Some advocate routine echocardiographic screening for youth sports participation or ICD placement at diagnosis. Any patient with syncope in whom HCM is suspected must be fully evaluated, as recurrence carries a high risk of sudden death.
Core Overview
Hypertrophic cardiomyopathy (HCM) is a genetic disorder of the cardiac sarcomere caused by numerous mutations, resulting in a hypertrophied, nondilated left ventricle (and rarely right ventricle) without another cause such as hypertension or aortic stenosis. Phenotypic expression is highly variable. Two major forms exist: nonobstructive HCM, accounting for approximately 75% of patients with an estimated annual mortality of ~1%, and obstructive hypertrophic cardiomyopathy (HOCM), accounting for ~25% with more severe disease and an estimated annual mortality of ~2%.
HCM can present at any age, from neonates to the elderly, but most cases manifest during childhood or adolescence, often coinciding with the pubertal growth spurt. Disease diagnosed at younger ages is typically more severe. A small subset progresses to reduced left ventricular systolic function later in life. Adult-onset presentations are not uncommon and are frequently misdiagnosed as asthma, COPD, deconditioning, or sleep apnea. Lethal ventricular arrhythmias are more common in younger patients, while supraventricular arrhythmias increase with age. Atrial fibrillation is common and often poorly tolerated. HCM is the most common cause of atraumatic sudden death in young athletes under 35 years of age. Prevalence is approximately 1 in 500 adults based on echocardiographic screening.
Structural and Pathophysiologic Features
Pathology is characterized by marked and irregular ventricular wall thickening with myofibrillar disarray and fibrin deposition, predominantly affecting the high-pressure left ventricle. Septal hypertrophy is usually more pronounced than free wall thickening. In obstructive disease, hypertrophy may regress if outflow obstruction is relieved. Some phenotypes demonstrate progressive wall thinning with age, typically following marked hypertrophy earlier in life. Diastolic stiffness leads to atrial dilation. Microvascular dysfunction occurs due to impaired vasodilation, intimal thickening, and perivascular collagen deposition.
Long-Term Outpatient Management Principles
Management focuses on avoiding volume depletion and excessive cardiac demand, with therapy tailored to hypertrophy severity and distribution. Pharmacologic treatment includes beta-blockers or verapamil to slow heart rate and prolong diastole. Implantable cardioverter-defibrillators are indicated in patients with prior syncope, cardiac arrest, family history of sudden death, nonsustained ventricular tachycardia, abnormal blood pressure response to exercise, or massive hypertrophy. Septal reduction strategies include alcohol septal ablation and surgical septal myectomy, with improving outcomes at experienced centers.
Genetic Risk Profile
HCM was the first cardiac disease with an identified genetic basis (1989). It follows an autosomal-dominant inheritance pattern with more than 10 associated genes, most encoding sarcomeric proteins. Over 700 distinct mutations have been identified, with high penetrance and marked phenotypic variability. Some genotypes carry significantly higher risk of sudden death. Routine genotype-based risk stratification remains impractical due to complexity and incomplete understanding of modifier genes and environmental factors. Certain mutations involving cell membrane pumps are associated with increased arrhythmogenic risk.
Clinical Presentation
Symptoms often correlate with exertion or sudden upright posture, both of which reduce venous return and ventricular filling. Severity depends on hypertrophy location and extent. Common symptoms include exertional dyspnea, shortness of breath, postprandial or exertional angina, presyncope, syncope, congestive heart failure, cardiovascular collapse, and dysrhythmias. Paroxysmal atrial fibrillation may precipitate rapid deterioration, particularly in heart failure, and increases thromboembolic risk. Ventricular tachycardia or fibrillation may cause sudden death, while bradyarrhythmias are rare.
Patients may have a history of septal myectomy or alcohol ablation, with associated risks of conduction abnormalities or septal rupture. High-risk individuals may have implanted defibrillators. A family history of unexplained sudden death or known HCM is a critical diagnostic clue.
Pediatric Considerations
Disease severity may increase during adolescence. Any child with unexplained syncope, especially during exertion, warrants detailed family history (standard three-generation pedigree) and specialist referral.
Physical Examination Findings
Findings may be absent or subtle in nonobstructive disease. In obstructive HCM, findings may include a loud left-sided S4, a double apical impulse, and a crescendo–decrescendo midsystolic murmur best heard at the left sternal border. The murmur increases with standing or Valsalva and decreases with squatting, recumbency, or handgrip. Mitral regurgitation is common; radiation to the axilla suggests associated mitral insufficiency.
Electrocardiographic Features
ECG is abnormal in over 90% of patients. Findings include T-wave inversion >1 mm in multiple leads, ST-segment depression >0.5 mm, deep Q waves (>3 mm or >40 ms) excluding leads III and aVR, prolonged P waves with negative terminal forces in V1, and nonspecific intraventricular conduction delay >140 ms. Athletic ECG variants require careful interpretation, especially in non–African-Caribbean athletes over 16 years.
Laboratory and Imaging Evaluation
Routine laboratory testing has no diagnostic value in the emergency setting. Genetic testing is outpatient-focused. Chest radiography is usually normal but may show left ventricular free wall bulging, atrial enlargement, or pulmonary vascular redistribution. Transthoracic echocardiography with Doppler is the diagnostic cornerstone, demonstrating LV wall thickness >15 mm in adults (or ≥13–14 mm with supportive features), small or normal LV cavity, systolic outflow obstruction, and diastolic dysfunction. In children, wall thickness ≥2 standard deviations above the mean is diagnostic. Cardiac MRI supplements echocardiography, offering detailed assessment of hypertrophy distribution and fibrosis. Stress thallium and PET imaging may identify ischemia.
Differential Diagnosis
Consider vasovagal syncope, heat illness, aortic or pulmonic stenosis, ventricular septal defect, mitral regurgitation or prolapse, and coronary artery disease. Angina or heart failure in HCM carries higher risk than in non-HCM populations.
Emergency Management Principles
Suspect HCM in patients who deteriorate with standard heart failure, ischemia, or supraventricular tachycardia treatment, and in young athletes collapsing during exertion. Patients are highly sensitive to preload reduction and impaired diastolic filling. Initial management includes airway stabilization, oxygen, IV access, cardiac monitoring, and pulse oximetry. Patients may need to remain supine.
Avoid routine vasodilators for CHF or angina, as they may precipitate collapse. If hypotension occurs, administer cautious fluid boluses. Even mild hypovolemia can significantly reduce cardiac output. Rate control and improved diastolic filling are central goals. Beta-blockers are first-line therapy; verapamil is useful but nifedipine is relatively contraindicated due to vasodilation.
Supraventricular dysrhythmias are treated initially with beta-blockers or calcium channel blockers. Amiodarone is the drug of choice for ventricular dysrhythmias or refractory cases. Early electrical cardioversion is recommended for new-onset atrial fibrillation with heart failure.
Key Medications
Amiodarone, propranolol, verapamil, phenylephrine (for refractory hypotension without inotropic effect), and diltiazem (contraindicated in children under 12) may be used with careful hemodynamic assessment. All medications must be evaluated for their impact on outflow tract obstruction.
Disposition Decisions
Admission is required for unexplained syncope, heart failure, angina, or hemodynamically significant tachydysrhythmias, often to ICU level care. Discharge may be considered only when hypertrophy is an incidental finding without personal or family history of syncope or sudden death, with urgent cardiology follow-up arranged. Patients must be counseled to avoid exertion or situations that reduce preload until evaluated.
Clinical Pitfalls and Key Insights
Genetic and phenotypic diversity complicates diagnosis and risk stratification. Some advocate routine echocardiographic screening for youth sports participation or ICD placement at diagnosis. Any patient with syncope in whom HCM is suspected must be fully evaluated, as recurrence carries a high risk of sudden death.
0 Comments
